http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
최재묵(Jae Mook Choi),이성학(Sung Hak Lee),김일환(Il Hwan Kim),박지은(Jie Eun Park),김덕열(Deog Yeor Kim),노현정(Hyun Jung Noh),김택로(Taekrho Kim),최광도(Do-Gwang Choi),김영훈(Young Hoon Kim),김진완(Jin Wan Kim),장준환(Joon Hwan Jan 한국독성학회 2004 Toxicological Research Vol.20 No.2
Safety pharmacological properties of CJ-11555, an anti-cirrhotic agent, were investigated in experimental animals and in vitro test system. CJ-11555 had no effects on normal body temperature in rats, motor coordination, chemoshock induced by pentetrazol, electric shock induced by electric shocker and writhing syndromes in mice at dose levels of 100, 300 and 1,000 mg/kg. CJ-11555 inhibited intestinal activity and prolonged hexobarbital-induced sleeping time in mice at the dose level of 1,000 mg/kg. CJ-11555 affected on general activity and behaviour tests in SD rats, such as<br/> lacrimation, ptosis, piloerection, decreased body tone, abnormal dispersion within the cage, diarrhoea, red colored faeces, slight hypothermia and decreased grooming, at the dose level of 1,000mg/kg in rats. CJ-11555 was effected on cardiovascular and respiratory system in anesthetized beagle dogs, such as tachycardia, increase of mean blood pressure and decrease of PR interval, decrease of respiratory rate and minute volume, at dose levels of 10 and <br/> 30mg/kg. However, these effects were also observed in vehicle treated anesthetized beagle dogs. In in vitro experiments, CJ-<br/> 11555 inhibited agonists (histamine, acetyl-choline or BaCl2) induced contraction of isolated guinea-pig at the concentration of 30x10-6 M. CJ-11555 was weekly inhibited hERG channel current at concentrations of 10 and 30x10-6 M, and IC50 was estimated to be higher than 30x10-6 M. Based on these results, it was concluded that CJ-11555 affected on cardiovascular and respiratory system, general activity and behaviour and hexobarbital-induced sleeping time at the dose level of 1,000 mg/kg and contraction of the smooth muscle and hERG channel current at the concentration of 30x10-6 M.
최재묵(Jae-Mook Choi),이성학(Sung-Hak Lee),김일환(Il-Hwan Kim),박지은(Jie-Eun Park),김덕열(Deog-Yeor Kim),노현정(Hyun-Jung Noh),김택로(Taekrho Kim),최광도(Do-Gwang Choi),김영훈(Young-Hoon Kim),김진완(Jin-Wan Kim),장준환(Joon-Hwan Jan 한국독성학회 2004 Toxicological Research Vol.20 No.1
Safety pharmacological properties of CJ-11555, an anti-cirrhotic agent, were investigated in experimental animals and in vitro test system. CJ-11555 had no effects on normal body temperature in rats, motor coordination, chemoshock induced by pentetrazol, electric shock induced by electric shocker and writhing syndromes in mice at dose levels of 100, 300 and 1,000 mg/kg. CJ-11555 inhibited intestinal activity and prolonged hexobarbital-induced sleeping time in mice at the dose level of 1,000 mg/kg. CJ-11555 affected on general activity and behaviour tests in SD rats, such as lacrimation, ptosis, piloerection, decreased body tone, abnormal dispersion within the cage, diarrhoea, red colored faeces, slight hypothermia and decreased grooming, at the dose level of 1,000<br/> mg/kg in rats. CJ-11555 was effected on cardiovascular and respiratory system in anesthetized beagle dogs, such as tachycardia, increase of mean blood pressure and decrease of PR interval, decrease of respiratory rate and minute volume, at dose levels of 10 and 30 mg/kg. However, these effects were also observed in vehicle treated anesthetized beagle dogs. In in vitro experiments, CJ-11555 inhibited agonists (histamine, acetyl-choline or BaCl2) induced contraction of isolated guinea-pig at the concentration of 30×10-6 M. CJ-11555 was weekly inhibited hERG channel current at concentrations of 10 and 30×10-6 M, and IC50 was estimated to be higher than 30×10-6 M. Based on these results, it was concluded that CJ-11555 affected on cardiovascular and respiratory system, general activity and behaviour and hexobarbital-induced sleeping time at the dose level of 1,000 mg/kg and contraction of the smooth muscle and hERG channel current at the concentration of 30×10-6 M.
골수염 치료제인 항생제비드 ( CJ-40003 ) 유효성분의 일반약리작용
김영훈(Young Hoon Kim),최재묵(Jae Mook Choi),온윤성(Yoon Seong On),연규정(Kyu Jeong Yeon),이윤하(Youn Ha Lee),김제학(Je Hak Kim),이영수(Young Soo Lee) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.1
A new antibiotic bead, CJ-40003 is a combination of three antibiotics, tobramycin, vancomycin and cefazolin embedded in bone cement, for the treatment of osteomyelitis. To evaluate the general pharmacological properties of CJ-40003, the effects of its active ingredients were investigated in mice, rats, dogs and isolated guinea pig ileum. The combination of three antibiotics (CA) did not affect general behavior, central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion when administered intravenously at the doses of 0.3, 1 and 3 mg/kg, respectively, into experimental animals. The CA had no effect on the contractile response of the isolated guinea pig ileum to various spasmogen at concentrations of 1, 3 and 10 ㎍/ml, respectively. In conclusion, the active ingredients of CJ-40003 showed no pharmacological effect in these studies.
유전자 재조합 B 형 간염 바이러스 표면 항원 , CJC-50100 의 일반약리작용
정성학(Seong Hak Jeong),최재묵(Jae Mook Choi),이남중(Nam Jung Lee),전형수(Hyung Soo Jeon),김연희(Yon Hee Kim),김재승(Jae Seung Kim),하석훈(Suk Hoon Ha),김영훈(Young Hoon Kim),이나경(Na Gyung Lee),김제학(Je Hak Kim),박완제(Wan Je Park 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33∼33.3 ㎍/㎏ i.m. for mice and rats and 3.3∼9.9 ㎍/㎏ i.v. for dogs. The concentrations of 0.002∼0.02 ㎍/mlwere used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 ㎍/man/60 kg.
김영훈(Young Hoon Kim),최재묵(Jae Mook Choi),홍선표(Sun Pyo Hong),문상범(Sang Bum Moon),김수옥(Soo Ok Kim),이윤하(Younha Lee),이영수(Young Soo Lee) 한국독성학회 1999 Toxicological Research Vol.15 No.2
To develop the second generation Japanese encephalitis (JE) vaccine, an attenuated JE vaccine virus strain SA14-14-2 (PDK) was adapted to Vero cell. The resulting virus SA14-14-2 (Vero) was purified using sucrose density gradient, inactivated with formalin and mixed with alum hydroxide to prepare the test vaccine named CJ-50003. The general pharmacological properties of CJ-50003 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.16~ 16 ㎍/kg i.m. for mice and rats and 0.48-1.6 ㎍/kg i.v. for dogs. The concentration of 0.0016-0.16 mg/ml were used for the assay with guinea pig ileum. lntramuscular administration of CJ-50003 at the doses did not alter general behavior and the responses for central nervous system, smooth muscles, gastrointestinal system, cardiovascular and respiratory system and water and electrolytes excretion. In summary, CJ-50003 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 5 ㎍/man/30 kg.
섬수 ( Bufonis Venenum ) 추출물의 약리작용
김영춘(Young Hoon Kim),정성학(Seong Hak Jeong),김종호(Jong Ho Kim),최재묵(Jae Mook Choi),지준환(Joon Hwan Ji),강재구(Jae Koo Kang),박종구(Jong Koo Park),김제학(Je Hak Kim),조희재(Hi Jae Cho) 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A Bufonis Venenum is a toad venom and its main components are bufadienolides, namely resibufogenin, bufalin and cinobufagin. The desensitizing effect of Bufonis Venenum is useful for the treatment of the premature ejaculation in Chinese medicine. But, minor components of Bufonis Venenum cause problems such as topical burning, pain, and erectile dysfunction. To clarify and eliminate the components responsible for these side effects, we prepared two extracts of Bufonis Venenum with either 70% ethanol or ethylacetate and tested their pharmacological effects. The extract of Bufonis Venenum with 70% ethanol produced pain response in rat hind paw, and exhibited contraction of rabbit corpus cavernosal muscle in vitro. On the other hand, the ethylacetate extract did not cause pain and smooth muscle contraction. The desensitizing effect of the ethylacetate extract was similar to that of the 70% ethanol extract. In conclusion, these results show that the extract of Bufonis Venenum with ethylacetate does not have the components causing side effects and deserve further study for therapeutic potential in premature ejaculation in men.
박지은(Jie-Eun Park),이성학(Sung-Hak Lee),최재묵(Jae-Mook Choi),김일환(Il-Hwan Kim),김덕열(Deog-Yeor Kim),노현정(Hyun-Jung Noh),김택로(Taekrho Kim),김영훈(Young-Hoon Kim),임지웅(Lim Jee Woong),김진환(Jin-Wan Kim),장준환(Jun-Hwan Chan 한국독성학회 2004 Toxicological Research Vol.20 No.2
To evaluate the genotoxicity of CJ-11555, an anti-cirrhotic agent, the reverse mutation test, chromosomal aberration test and in vivo micronucleus test in rats were performed. In the reverse mutation test, the treatment of CJ-11555 at doses of 33.3, 100, 333, 1000, 3330 and 5000 mg/plate with and without S9 did not induce mutagenicity in Salmonella typhimurium TA98, TA100, TA1535, TA1537, and Escherichia coli ( E. coli) WP2 uvrA. In chromosomal aberration test, CJ-11555 did not induce structural a chromosomal aberration in Chinese hamster ovary (CHO) cells with and without metabolic activation at all doses. In micronucleus test, CJ-11555 did not induce any statistically significant increases in micronucleated polychromatic erythrocyte (MNPCE) at doses of 500, 1000, and<br/> 2000 mg/kg. These results suggest that CJ-11555 might not have a mutagenic potential under the conditions in this study.